Medicine composition of alprostadil and Chuanhuning/Yanhuning liposome and its prepn

A technology of alprostadil and Yanhuning, applied in the field of alprostadil and Chuanhuning/Yanhuning liposome combination medicine and preparation thereof, can solve the problems of pyrogen-like reaction, allergic reaction, liver function damage, etc. Use dose, improve the therapeutic index, and promote the effect of hepatocyte regeneration

Inactive Publication Date: 2007-08-22
江苏德伦生物制药有限公司
0 Cites 5 Cited by

AI-Extracted Technical Summary

Problems solved by technology

The existing Chuanhuning and Yanhuning drugs have liver fun...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Abstract

The present invention relates to medicine composition of alprostadil and Chuanhuning/Yanhuning liposome and its preparation process. The nanometer liposome medicine contains the mixture of alprostadil and Chuanhuning/Yanhuning in the weight ratio of 0.1-1.0 to 50-300 in 10.1-80.2 weight portions, the mixture of soybean lecithin and yolk lecithin in the weight ratio of 4 to 1 in 88-440 weight portions, the mixture of cholesterol and beta-sitosterol n the weight ratio of 9 to 1 in 40-200, polyethylene glycol in 4000 15-40 weight portions, sodium glucuronate in 100 -280 weight portions and vitamin C in 160-800 weight portions. The medicine of the present invention may be used in antagonizing pneumonia adenovirus and influenza virus.

Application Domain

Technology Topic

Image

  • Medicine composition of alprostadil and Chuanhuning/Yanhuning liposome and its prepn
  • Medicine composition of alprostadil and Chuanhuning/Yanhuning liposome and its prepn
  • Medicine composition of alprostadil and Chuanhuning/Yanhuning liposome and its prepn

Examples

  • Experimental program(5)

Example Embodiment

[0029] Example 1:
[0030] This embodiment provides a kind of nano liposome drug, comprising alprostadil and Chuanhuning/Yanhuning, comprising the following raw materials in parts by weight:
[0031] Alprostadil and Chuanhuning/Yanhuning
[0032] Mixture 80.2 in a weight ratio of 0.1:300;
[0033] 4:1 mixture of soybean lecithin and egg yolk lecithin in weight ratio 440;
[0034] Cholesterol and β-sitosterol weight ratio 9: 1 mixture 200;
[0035] Macrogol 4000 40;
[0036] Sodium Glucuronate 280;
[0037] Vitamin C 800.
[0038] The Chuanhuning/Yanhuning refers to the mixture of Chuanhuning and Yanhuning in a weight ratio of 3:1 or Chuanhuning alone.
[0039] The preparation method of above-mentioned medicine, the steps are as follows:
[0040] (1) Get the mixture of Alprostadil and Chuanhuning/Yanhuning weight ratio 0.1: 300, soybean lecithin and egg yolk lecithin mixture, cholesterol and β-sitosterol weight ratio 9: 1 mixture dissolved in ethanol or ether In, make a solution;
[0041] (2) Get the solution prepared in step (1) and evaporate to dryness in a rotary evaporator to make a phospholipid film;
[0042] (3) hydrating the phospholipid film prepared in step (2) with 0.01M, pH6.0-7.0 phosphate buffer solution to obtain a phospholipid film suspension, the optimal concentration of phospholipid is 0.02M;
[0043] (4) Dissolve polyethylene glycol 4000, sodium glucuronate, and vitamin C in a 0.01M, pH6.0-7.0 phosphate buffer, ultrafilter with an ultrafiltration membrane with a molecular weight cut-off of 5000 Daltons, take the filtrate, and remove Bacterial endotoxin;
[0044] (5) The phospholipid film suspension prepared in step (3) is made into a liposomal drug carrier with an average particle diameter of 100nm with a mini-extruder micro-extruder, and added to the filtrate prepared in step (4), in a water bath After ultrasonic treatment of 4-50W/L for 5-10 minutes, filter through a 220nm filter membrane, and take the filtrate;
[0045] (6) Making the filtrate prepared in step (5) into a pharmaceutically acceptable dosage form.
[0046] Specifically, the pharmaceutically acceptable dosage forms are freeze-dried powder injections, enteric-coated capsules, enteric-coated tablets, sprays, and nasal drops.
[0047] The curative effect verification of the medicine prepared in the present embodiment is as follows:
[0048] Induce pneumonia model mice with A1 type influenza virus, 18-20 grams in weight, with 25μg/kg alprostadil/80mg/kg Yanhuning/Chuanhuning (treatment group 1) or 25μg/kg alprostadil/80mg/kg Chuanhuning (Treatment group 2) Dosage: Tail vein injection, once a day, for 7 days, 50 rats in the treatment group. The first positive control group and the second positive control group used Yanhuning and Chuanhuning alone, the dose was 80 mg/kg, and the others were the same as those in the treatment group.
[0049] The survival rate, pyrogenic reaction rate, vomiting and diarrhea rate were counted.
[0050] The test results are as follows:

Example Embodiment

[0051] Example 2:
[0052] This embodiment provides a kind of nano liposome drug, comprising alprostadil and Chuanhuning/Yanhuning, comprising the following raw materials in parts by weight:
[0053] Alprostadil and Chuanhuning/Yanhuning
[0054] Mixture 10.1 in a weight ratio of 0.1:500;
[0055] 4:1 mixture of soybean lecithin and egg yolk lecithin by weight 88;
[0056] 9:1 ​​mixture of cholesterol and β-sitosterol by weight 40;
[0057] Polyethylene glycol 4000 15;
[0058] Sodium Glucuronate 100;
[0059] Vitamin C 160.
[0060] The Chuanhuning/Yanhuning refers to the mixture of Chuanhuning and Yanhuning in a weight ratio of 2:1 or Chuanhuning alone.
[0061] The preparation method of above-mentioned medicine refers to embodiment 1.
[0062] The curative effect verification of the medicine prepared in the present embodiment is as follows:
[0063] Induce pneumonia model mice with A1 type influenza virus, 18-20 grams in weight, with 20μg/kg alprostadil/10mg/kg Yanhuning/Chuanhuning (treatment group 1) or 20μg/kg alprostadil/10mg/kg Chuanhuning (Treatment group 2) Dosage: Tail vein injection, once a day, for 7 days, 50 rats in the treatment group. The drugs of the first positive control group and the second positive control group were Yanhuning and Chuanhuning respectively, the dosage was 10 mg/kg, and the others were the same as those of the treatment group.
[0064] The survival rate, pyrogenic reaction rate, vomiting and diarrhea rate were counted.
[0065] The test results are as follows:

Example Embodiment

[0066] Example 3:
[0067] This embodiment provides a kind of nano liposome drug, comprising alprostadil and Chuanhuning/Yanhuning, comprising the following raw materials in parts by weight:
[0068] Alprostadil and Chuanhuning/Yanhuning
[0069] Mixture 80.2 in weight ratio 1.0:266;
[0070] 4:1 mixture of soybean lecithin and egg yolk lecithin by weight 88;
[0071] Cholesterol and β-sitosterol weight ratio 9: 1 mixture 200;
[0072] Polyethylene glycol 4000 15;
[0073] Sodium Glucuronate 100;
[0074] Vitamin C 800.
[0075] The Chuanhuning/Yanhuning refers to the mixture of Chuanhuning and Yanhuning in a weight ratio of 3:1 or Yanhuning alone.
[0076] The preparation method of above-mentioned medicine refers to embodiment 1.
[0077] The curative effect verification of the medicine prepared in the present embodiment is as follows:
[0078] Induce pneumonia model mice with A1 type influenza virus, 18-20 grams in weight, with 300μg/kg alprostadil 80mg/kg Yanhuning/Chuanhuning (treatment group 1) or 300μg/kg alprostadil 80mg/kg Yanhuning (Treatment group 2) Dosage: Tail vein injection, once a day, for 7 days, 50 rats in the treatment group. The drugs of the first positive control group and the second positive control group were Yanhuning and Chuanhuning respectively, the dosage was 80 mg/kg, and the others were the same as those of the treatment group.
[0079] The survival rate, pyrogenic reaction rate, vomiting and diarrhea rate were counted.
[0080] The test results are as follows:
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Similar technology patents

Maca preparation and preparation method thereof

ActiveCN104873561AImprove curative effectImprove stabilityNervous disorderHydrocarbon active ingredientsIschemic vascular dementiaCompounded preparations
Owner:华北制药秦皇岛有限公司

Classification and recommendation of technical efficacy words

  • Lower dose
  • Improve curative effect

Composite miticide for farmland and fruit trees

InactiveCN102484990AExcellent control effectLower doseBiocideAnimal repellantsAvermectinFruit tree
Owner:LIANBAO CROP TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products